Guardant Health, a Redwood City, CA-based developer of cancer diagnostic technologies, completed an over $30m Series B financing.
The round was led by Khosla Ventures with participation from existing investor Sequoia Capital and new investor Pejman Mar Ventures. In conjunction with the funding, Samir Kaul, founding partner of Khosla Ventures, will join Guardant’s board of directors.
The company intends to use the funds for the commercial expansion of its GUARDANT360™ non-invasive tumor sequencing test.
Led by Helmy Eltoukhy, Ph.D., co-founder and chief executive officer, Guardant Health provides GUARDANT360, a pan-cancer test that aids oncologists in making more informed, personalized treatment decisions based upon the patient’s specific genomic alterations across dozens of genes via a simple blood test.
The test is built on Digital Sequencing™, a proprietary method of capturing and genetically profiling trace fragments of tumor DNA that are shed into the blood stream (“cell-free” DNA), and provides high-fidelity tumor sequencing information at the single-molecule level.